RxDoctor Payments Data

William Shaw Jr, MD

Internal Medicine · Greensboro, NCNPI 1568482651

Payments from drug & device makers

$7,492in general payments, 2019–2025

Across 520 payments — averaging $14.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$856
  • Lilly USA, LLC$732
  • Amgen$681
  • Novo Nordisk$669
  • AstraZeneca$374
  • Boehringer Ingelheim$342
  • plus $4K from 53 others

What the payments were for

  • Food & beverage$7,479100%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)53$856
Lilly USA, LLC48$732
Amgen52$681
Novo Nordisk67$669
AstraZeneca19$374
Boehringer Ingelheim23$342
Sanofi-aventis U.S. LLC22$325
Pfizer19$251
GSK18$251
Astellas Pharma US Inc15$206
Abbott17$205
Otsuka America Pharmaceutical, Inc.8$175
Radius Health, Inc.9$172
Sumitomo Pharma America, Inc.8$156
Novartis10$147
Takeda Pharmaceuticals U.S.A., Inc.11$137
Exact Sciences8$125
Dexcom, Inc.7$110
Collegium Pharmaceutical, Inc.7$99
Amarin Pharma, Inc.6$86
Merck6$78
Sunovion Pharmaceuticals Inc.6$78
Lifescan, Inc.5$74
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC5$74
Xeris Pharmaceuticals, Inc.5$67
Biohaven Pharmaceutical Holding Company Ltd.4$67
E.r. Squibb & Sons, L.L.C.5$65
Mannkind Corporation5$65
Amneal Pharmaceuticals LLC4$56
Johnson & Johnson4$50
Cequr Corporation2$44
Bayer3$44
Biohaven Pharmaceuticals, Inc.3$43
IBSA Pharma Inc.3$43
Nestle Healthcare Nutrition Inc.3$40
Medtronic(2 entities)3$37
Regeneron Healthcare Solutions, Inc.2$34
Insulet Corporation2$34
Antares Pharma, Inc.2$33
Aimmune Therapeutics, Inc.1$30
Daiichi Sankyo Inc.1$26
Ironwood Pharmaceuticals, Inc2$22
Viatris Specialty LLC1$21
Sanofi Pasteur Inc.1$21
Avanir Pharmaceuticals, Inc.1$20
ARS Pharmaceuticals Operations, Inc.1$20
Seqirus USA Inc1$20
Idorsia Pharmaceuticals US Inc1$19
Irhythm Technologies, Inc.1$19
Shire North American Group Inc1$18
Genentech USA, Inc.1$17
Phathom Pharmaceuticals, Inc.1$16
Esperion Therapeutics, Inc.1$15
Shield Therapeutics Inc1$15
Currax Pharmaceuticals LLC1$14
Tolmar, Inc.1$14
Philips North America LLC1$14
Valeritas, Inc.1$13
Teva Pharmaceuticals USA, Inc.1$12

How this compares

$7,492 in reported general payments places this provider in the 90th percentile of 3,302 internal medicine providers in North Carolina.

See all internal medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$179,514
Medicare patients
247
Services billed
4,133

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide100$155,451
EliquisApixaban148$148,462
JardianceEmpagliflozin121$132,318
OzempicSemaglutide76$76,069
MyrbetriqMirabegron116$68,501
TrulicityDulaglutide49$65,220
Repatha SureclickEvolocumab71$51,063
FarxigaDapagliflozin Propanediol53$47,559
Tresiba Flextouch U-200Insulin Degludec34$47,011
Trelegy ElliptaFluticasone/Umeclidin/Vilanter56$36,205
KerendiaFinerenone31$25,803
LinzessLinaclotide35$24,527
Praluent PenAlirocumab21$18,290
SynthroidLevothyroxine Sodium154$17,070
PaxlovidNirmatrelvir/Ritonavir48$13,794

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$732$220,671149 claims
PfizerEliquis, Paxlovid, Premarin$251$170,150222 claims
Boehringer IngelheimJardiance$342$132,318121 claims
Novo NordiskOzempic$669$76,06976 claims
Astellas Pharma US IncMyrbetriq$206$68,501116 claims
AstraZenecaFarxiga, Symbicort$374$53,67273 claims
GSKTrelegy Ellipta, Breo Ellipta$251$48,26680 claims
AbbVieLinzess, Synthroid$856$41,598189 claims
BayerKerendia$44$25,80331 claims
Johnson & JohnsonXarelto$50$11,91515 claims
MerckLagevrio (Eua)$78$8,37913 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$56$5,736434 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,302 internal medicine providers in North Carolina.

Other internal medicine in Greensboro

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →